LncRNA BASP1-AS1 Interacts with YBX1 to Regulate Notch Transcription and Drives the Malignancy of Melanoma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2021 Sep 17

PMID 34533860

Citations 23

Authors

Yaling Li

YaLi Gao

Xueli Niu

Mingsui Tang

Jingyi Li

Bing Song

Xiuhao Guan

Affiliations

Soon will be listed here.

Abstract

Melanoma is a fatal skin malignant tumor with a poor prognosis. We found that long noncoding RNA BASP1-AS1 is essential for the development and prognosis of melanoma. The methylation, RNA sequencing, copy number variation, mutation data, and sample follow-up information of melanoma from The Cancer Genome Atlas (TCGA) were analyzed using weighted gene co-expression network analysis and 366 samples common to the three omics were selected for multigroup clustering analysis. A four-gene prognostic model (BASP1-AS1, LOC100506098, ARHGAP27P1, and LINC01532) was constructed in the TCGA cohort and validated using the GSE65904 series. The expression of BASP1-AS1 was upregulated in melanoma tissues and various melanoma cell lines. Functionally, the ectopic expression of BASP1-AS1 promoted cell proliferation, migration, and invasion in both A375 and SK-MEL-2 cells. Mechanically, BASP1-AS1 interacted with YBX1 and recruited it to the promoter of NOTCH3, initiating its transcription process. The activation of the Notch signaling then resulted in the transcription of multiple oncogenes, including c-MYC, PCNA, and CDK4, which contributed to melanoma progression. Thus, BASP1-AS1 could act as a potential biomarker for cutaneous malignant melanoma.

Citing Articles

Unravelling the Regulatory Roles of lncRNAs in Melanoma: From Mechanistic Insights to Target Selection.

Moras B, Sissi C Int J Mol Sci. 2025; 26(5).

PMID: 40076754 PMC: 11900516. DOI: 10.3390/ijms26052126.

MLLT3 Regulates Melanoma Stemness and Progression by Inhibiting HMGB1 Nuclear Entry and MAGEA1 MC Modification.

Li Y, Liu H, Li J, Fu C, Jiang B, Chen B Adv Sci (Weinh). 2024; 12(10):e2408529.

PMID: 39716999 PMC: 11904942. DOI: 10.1002/advs.202408529.

LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies.

Beatriz Cristina Biz T, Carolina de Sousa C, Frank John S, Miriam Galvonas J RNA Biol. 2024; 21(1):81-93.

PMID: 39498940 PMC: 11540095. DOI: 10.1080/15476286.2024.2421672.

A signature of seven hypoxia-related lncRNAs is a potential biomarker for predicting the prognosis of melanoma.

Wu Y, Yin S, Li C, Zhao L, Song M, Yu Y Am J Cancer Res. 2024; 14(4):1712-1729.

PMID: 38726277 PMC: 11076246. DOI: 10.62347/LHKW3124.

Low expression of predicts poor survival outcomes and is associated with immune infiltration in breast cancer.

Liu X, Cui Q, Qin N Transl Cancer Res. 2024; 13(3):1225-1240.

PMID: 38617516 PMC: 11009814. DOI: 10.21037/tcr-23-1231.

References

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Suresh P, Tsutsumi R, Venkatesh T . YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. Eur J Cell Biol. 2018; 97(3):163-167. DOI: 10.1016/j.ejcb.2018.02.003. View

Palomero T, Lim W, Odom D, Sulis M, Real P, Margolin A . NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006; 103(48):18261-6. PMC: 1838740. DOI: 10.1073/pnas.0606108103. View

Zou Z, Ma C, Medoro L, Chen L, Wang B, Gupta R . LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget. 2016; 7(38):61741-61754. PMC: 5308687. DOI: 10.18632/oncotarget.11437. View

Li Y, Gao Y, Niu X, Tang M, Li J, Song B . LncRNA BASP1-AS1 interacts with YBX1 to regulate Notch transcription and drives the malignancy of melanoma. Cancer Sci. 2021; 112(11):4526-4542. PMC: 8586662. DOI: 10.1111/cas.15140. View

Nowell C, Radtke F . Notch as a tumour suppressor. Nat Rev Cancer. 2017; 17(3):145-159. DOI: 10.1038/nrc.2016.145. View

George D, Armenio V, Katz S . Combinatorial immunotherapy for melanoma. Cancer Gene Ther. 2016; 24(3):141-147. DOI: 10.1038/cgt.2016.56. View

Aster J, Pear W, Blacklow S . The Varied Roles of Notch in Cancer. Annu Rev Pathol. 2016; 12:245-275. PMC: 5933931. DOI: 10.1146/annurev-pathol-052016-100127. View

Kuwano M, Shibata T, Watari K, Ono M . Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019; 110(5):1536-1543. PMC: 6500994. DOI: 10.1111/cas.14006. View

10.

Peng Z, Wang J, Shan B, Li B, Peng W, Dong Y . The long noncoding RNA LINC00312 induces lung adenocarcinoma migration and vasculogenic mimicry through directly binding YBX1. Mol Cancer. 2018; 17(1):167. PMC: 6260658. DOI: 10.1186/s12943-018-0920-z. View

11.

Cheng S, Li Z, Zhang W, Sun Z, Fan Z, Luo J . Identification of IL10RA by Weighted Correlation Network Analysis and Validation of Its Association With Prognosis of Metastatic Melanoma. Front Cell Dev Biol. 2021; 8:630790. PMC: 7820192. DOI: 10.3389/fcell.2020.630790. View

12.

Sharma V, Calvo J, Draheim K, Cunningham L, Hermance N, Beverly L . Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol. 2006; 26(21):8022-31. PMC: 1636748. DOI: 10.1128/MCB.01091-06. View

13.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L . Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016; 63:201-17. DOI: 10.1016/j.ejca.2016.05.005. View

14.

Ozsolak F, Milos P . RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2010; 12(2):87-98. PMC: 3031867. DOI: 10.1038/nrg2934. View

15.

Gao Y, Li Y, Niu X, Wu Y, Guan X, Hong Y . Identification and Validation of Prognostically Relevant Gene Signature in Melanoma. Biomed Res Int. 2020; 2020:5323614. PMC: 7238332. DOI: 10.1155/2020/5323614. View

16.

Xu Y, Qiu M, Shen M, Dong S, Ye G, Shi X . The emerging regulatory roles of long non-coding RNAs implicated in cancer metabolism. Mol Ther. 2021; 29(7):2209-2218. PMC: 8261164. DOI: 10.1016/j.ymthe.2021.03.017. View

17.

Mordovkina D, Lyabin D, Smolin E, Sogorina E, Ovchinnikov L, Eliseeva I . Y-Box Binding Proteins in mRNP Assembly, Translation, and Stability Control. Biomolecules. 2020; 10(4). PMC: 7226217. DOI: 10.3390/biom10040591. View

18.

Ravindran Menon D, Luo Y, Arcaroli J, Liu S, KrishnanKutty L, Osborne D . CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res. 2018; 78(23):6561-6574. PMC: 6279496. DOI: 10.1158/0008-5472.CAN-18-0330. View

19.

Zhang Y, Huang Y, Wang D, Yang B, Yan H, Lin L . LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Theranostics. 2020; 10(23):10823-10837. PMC: 7482804. DOI: 10.7150/thno.47830. View

20.

Peng W, Koirala P, Mo Y . LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017; 36(41):5661-5667. PMC: 6450570. DOI: 10.1038/onc.2017.184. View